| Autor: |
Nan Shen, Lihong Zhang, Jing Yang, Yongqiang Lin, Xinyu Liu, Xudong Cai, Juan Cao, Qiang Zhu, Xun Luo, Xin Wan, Henglan Wu, Jianming Ye, Chunyan Shan, Hua Xie, Yifan Wu, Yanping Cao, Jianmin Wang, Xiaoyong Yu, Huimin Wang, Jingdong He, Shaojiang Tian, Fenglei Wu, Xinxin Jiang, Lu Li, Li Zuo, Zhaohua Wang, Changying Xing, Xun Yin, Jianrong Zhao, Cong Ma, Gang Long, Qing Li, Yao Hu, Yifan Shi, Hongli Lin |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Pharmacology, Vol 15 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1663-9812 |
| DOI: |
10.3389/fphar.2024.1398953 |
| Popis: |
Introduction: Sodium zirconium cyclosilicate (SZC) is a nonabsorbed cation-exchanger approved in China for the treatment of hyperkalemia [HK; serum potassium (sK+) levels >5.0 mmol/L]. This is the first real-world study aimed to assess the effectiveness, safety, and treatment patterns of SZC in Chinese patients with HK. Here we present the results of the first interim analysis.Methods: This multicenter, prospective, cohort study included patients aged ≥18 years with documented HK within 1-year before study enrollment day. These patients were followed up for 6 months from the enrollment day after initiating SZC treatment. The treatment was categorized into correction phase (FAS-P1) and maintenance phase (FAS-P2 new and ongoing users). Subgroup analysis was performed in patients on hemodialysis (FAS-H). The primary objective was evaluation of safety profile of SZC; secondary objectives included assessment of treatment patterns of SZC and its effectiveness.Results: Of 421 screened patients, 193, 354, and 162 patients were enrolled in the FAS-P1, FAS-P2, and FAS-H groups, respectively. sK+ levels were reduced significantly from 5.9 mmol/L to 5.0 mmol/L after the correction phase. For the maintenance phase, the mean sK+ levels were maintained at 5.2 mmol/L and 5.0 mmol/L in the FAS-P2 new and ongoing user, respectively, and 5.3 mmol/L in the FAS-H subgroup. A considerable proportion of patients showed normokalemia after 48 h of SZC treatment (FAS-P1:51.3%) which was maintained up to 6 months in the maintenance phase (FAS-P2:44%). SZC was well-tolerated.Conclusion: SZC was effective and safe for the treatment of HK in real-world clinical practice in China. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
